S&P 500

5.346,99

-0,11%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Freeline Therapeutics Holdings PLC (FRLN)
Freeline Therapeutics Holdings PLC (FRLN) Notícias

FRLN

Freeline Therapeutics (FRLN)

Freeline Therapeutics Holdings PLC

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:FRLN

1 2 3 4 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
24/04/2024	17:00	GlobeNewswire Inc.	Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
26/02/2024	02:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
22/02/2024	18:38	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
22/02/2024	18:28	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
20/02/2024	17:22	Edgar (US Regulatory)	Form SC 13E3/A - Going private transaction by certain issuers: [Amend]	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
20/02/2024	09:13	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
20/02/2024	09:00	GlobeNewswire Inc.	Acquisition of Freeline by Syncona Becomes Effective	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
12/02/2024	14:00	GlobeNewswire Inc.	Freeline Shareholders Approve Acquisition by Syncona	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
08/12/2023	19:21	Edgar (US Regulatory)	Form SC 13E3 - Going private transaction by certain issuers	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
22/11/2023	09:30	GlobeNewswire Inc.	Syncona to Acquire Freeline Therapeutics	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
25/10/2023	03:01	GlobeNewswire Inc.	Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
16/10/2023	08:00	GlobeNewswire Inc.	Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
04/10/2023	08:00	GlobeNewswire Inc.	Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
15/08/2023	08:00	GlobeNewswire Inc.	Freeline Reports Second Quarter 2023 Financial Results and Business Highlights	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
08/08/2023	08:30	GlobeNewswire Inc.	Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
31/07/2023	08:30	GlobeNewswire Inc.	Freeline to Participate in Upcoming Investor Conferences	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
25/07/2023	08:30	GlobeNewswire Inc.	Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
26/06/2023	08:31	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
26/06/2023	08:30	GlobeNewswire Inc.	Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
02/06/2023	09:00	GlobeNewswire Inc.	Freeline to Present at 2023 Jefferies Healthcare Conference	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
30/05/2023	08:30	GlobeNewswire Inc.	Freeline Reports First Quarter 2023 Financial Results and Business Highlights	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
22/05/2023	09:00	GlobeNewswire Inc.	Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
12/05/2023	09:05	GlobeNewswire Inc.	Freeline Completes ADS Ratio Change	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
21/04/2023	09:54	Edgar (US Regulatory)	Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
21/04/2023	08:00	GlobeNewswire Inc.	Freeline Announces Proposed ADS Ratio Change	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
12/04/2023	09:00	GlobeNewswire Inc.	Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
04/04/2023	08:03	Edgar (US Regulatory)	Annual and Transition Report (foreign Private Issuer) (20-f)	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
04/04/2023	08:00	GlobeNewswire Inc.	Freeline Reports Full Year 2022 Financial Results and Provides Corporate Update	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
28/03/2023	08:00	GlobeNewswire Inc.	Freeline Therapeutics to Host Full Year 2022 Financial Results Call	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC
14/02/2023	15:55	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:FRLN	Freeline Therapeutics Holdings PLC